Cotinine: A Literature Course on What the Studies Report

Cotinine is the principal metabolite of nicotine and a small-molecule alkaloid rather than a peptide, and the published literature has used it in two very different ways: as a measurable marker of tobacco smoke exposure, and as an experimental compound administered in preclinical models, where researchers described nicotine and cotinine as agents that target MD2 and inhibit TLR4 signalling (PMID 34557761). This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication, tobacco exposure or laboratory testing. It describes what studies did and reported, not what anyone should do.

The six modules below move from definition to mechanism, then to reported outcomes, adverse findings, pharmacokinetics and regulatory status. Each module closes with an explicit statement of what the evidence cannot support.

Module 1 — What Cotinine Is and How It Has Been Studied

Definition and class

Cotinine is a pyridine-containing alkaloid formed in the body from nicotine. Chemically it belongs to the same tobacco alkaloid family as nicotine and is not a peptide, a protein fragment or a hormone analogue. Papers in this course describe it explicitly as "nicotine and its metabolite cotinine" when the two are studied together as pharmacological agents (PMID 34557761).

Origin and forms encountered in the literature

Three practical forms appear across the verified studies. First, cotinine as an endogenous analyte: researchers measured it in serum to classify smokers and non-smokers (PMID 29465001) and in urine of children living with domestic cigarette smoke (PMID 29456398). Second, cotinine as a clinical or population biomarker, tracked in daily cigarette smokers using national survey data (PMID 24291557) and compared between people who smoked and people who chewed tobacco (PMID 33107452). Third, cotinine as an administered test compound in animal work on fear extinction and astrocyte survival (PMID 32300297) and in transgenic Tg6799 mice modelling Alzheimer-like pathology (PMID 25100990).

Study designs represented

• Cross-sectional human measurement studies in smokers, tobacco chewers and exposed children.
• Population surveillance analyses of serum concentrations over time (PMID 24291557).
• A clinical process study in which cotinine testing was applied before total joint arthroplasty (PMID 30579712).
• Rodent pharmacology and toxicology experiments, including oocyte work in mice (PMID 35191979).
• Veterinary analytical work that detected cotinine in canine semen as evidence of tobacco smoke exposure (PMID 39728938).

Limits of the evidence in Module 1: the verified set contains no randomised controlled trial of cotinine given to humans as a therapeutic. Most human data are observational measurements of exposure, so they describe who had cotinine in their body and at what concentration — not what cotinine did to them.

Module 2 — Mechanism as Described in the Literature

Nicotinic acetylcholine receptor signalling

The most frequently invoked mechanism is action at nicotinic acetylcholine receptors. In a 2020 pharmacology study, cotinine enhanced fear extinction and supported astrocyte survival through mechanisms that the authors attributed to nicotinic acetylcholine receptor signalling (PMID 32300297). That framing positions cotinine as a weak, long-lived ligand at the same receptor family as its parent compound rather than as an inert waste product.

Innate immune signalling via MD2 and TLR4

A separate line of work moved outside the cholinergic system: researchers reported that both nicotine and cotinine targeted the accessory protein MD2 and inhibited toll-like receptor 4 signalling (PMID 34557761). This describes an anti-inflammatory molecular interaction at the level of pattern-recognition signalling, distinct from receptor-level cholinergic effects.

Pathology-level mechanisms in disease models

In transgenic Tg6799 mice, cotinine was reported to halt the advance of Alzheimer's disease-like pathology and associated depressive-like behaviour, which the authors interpreted as an effect on amyloid-related pathology and mood-associated circuitry in that model (PMID 25100990). In the opposite direction, cotinine exposure was described as a driver of oocyte deterioration in mice, with melatonin co-treatment preventing that deterioration (PMID 35191979), implying oxidative or stress-related damage pathways in reproductive tissue.

Mechanism versus marker

Human studies in this set generally treat cotinine as a marker of smoke intake rather than as the causal agent. A 2022 study examined vascular inflammation and oxidative stress in smokers through interleukin-6 and superoxide dismutase, with cotinine used as the exposure measure (PMID 36147199); the reported biology there reflects smoking, not isolated cotinine administration.

Limits of the evidence in Module 2: the receptor and MD2/TLR4 mechanisms come from experimental systems, and the two mechanistic directions (neuroprotective signalling versus reproductive damage) have not been reconciled in a single model. No verified study demonstrated a mechanism in living humans given cotinine.

Module 3 — Reported Outcomes by Study

The table below summarises the model, the endpoint measured and what researchers reported. It is a description of published findings, not a statement of benefit.

Limits of the evidence in Module 3: the two neurological findings are single-model animal studies without human replication in this set; the human studies measured cotinine as an exposure index, so their outcomes describe smoking or testing programmes rather than effects of cotinine itself. None of these results establishes a clinical benefit of cotinine in people.

Module 4 — Cotinine Side Effects: What Studies Report

Reproductive findings in animals

The clearest adverse finding attributed directly to cotinine exposure is reproductive: researchers reported that cotinine exposure deteriorated oocytes in mice and that melatonin co-treatment prevented that deterioration (PMID 35191979). In dogs, cotinine was detected in semen as a marker of tobacco smoke exposure, placing the metabolite in reproductive fluid of a second species (PMID 39728938).

Inflammatory and oxidative-stress markers in humans

In smokers, cotinine was used alongside interleukin-6 and superoxide dismutase to detect vascular inflammation and oxidative stress, so higher exposure accompanied altered inflammatory and antioxidant markers in that study (PMID 36147199). Because cotinine there indexed smoking rather than being administered, the reported marker changes cannot be assigned to the metabolite alone.

Involuntary exposure

Urinary cotinine was detectable in Indonesian children exposed to domestic cigarette smoke, documenting internal dose in people who did not smoke (PMID 29456398). Population data likewise tracked serum cotinine concentrations in daily cigarette smokers across a decade of survey cycles (PMID 24291557).

What the safety record does not contain

• No verified human trial administered cotinine and catalogued adverse events by frequency.
• No verified study reported serious adverse events, discontinuation rates or laboratory abnormalities from cotinine given as a drug.
• No verified study examined long-term safety, pregnancy outcomes in humans, or drug–drug interactions for administered cotinine.

Limits of the evidence in Module 4: the adverse-event picture is built from one rodent reproductive study, animal detection work and human exposure-marker studies. An absence of reported harms in this set is a gap in the literature, not a demonstration of safety.

Module 5 — Pharmacokinetics Where Data Exist

Animal pharmacokinetics

The most direct kinetic data come from a 2020 analytical study that performed in vivo quantification and pharmacokinetic studies of cotinine in mice after smoke exposure using LC-MS/MS (PMID 31756277). The relevant design point is that exposure occurred by inhaled smoke rather than by administration of purified cotinine, so the kinetics described formation and disposition of the metabolite after nicotine intake.

Human concentration data as a surrogate

Human work in this set characterised concentrations rather than classical pharmacokinetic parameters. Serum cotinine cut-offs were revised and extended to separate smokers from non-smokers, a use that depends on the metabolite's comparatively long persistence relative to nicotine (PMID 29465001). Serum cotinine was also estimated and compared between individuals who smoked and individuals who chewed tobacco, showing that route of tobacco use shaped measured concentrations (PMID 33107452). At population scale, serum concentrations among daily cigarette smokers were tracked over successive survey years (PMID 24291557).

Matrices in which cotinine has been measured

• Serum: classification of smoking status and population trend analysis (PMID 29465001).
• Urine: exposure assessment in children living with household smoke (PMID 29456398).
• Semen: detection in dogs as evidence of smoke exposure (PMID 39728938).
• Plasma/tissue in rodents: LC-MS/MS quantification after smoke exposure (PMID 31756277).

Limits of the evidence in Module 5: the verified set does not provide human half-life, bioavailability, clearance or volume-of-distribution figures for administered cotinine, and the rodent data reflect smoke exposure rather than dosing of the pure compound. No dose figures are stated on this page because the verified sources do not supply them.

Module 6 — Regulatory Status, Stated Factually

Several factual distinctions matter when reading cotinine literature.

1. Cotinine as a laboratory test. Cotinine measurement is an established analytical and clinical laboratory activity: serum cut-offs have been published for classifying smoking status (PMID 29465001), and a surgical programme used cotinine testing in the pathway toward total joint arthroplasty (PMID 30579712). Testing for a biomarker is regulated as a diagnostic activity, not as a therapy.
2. Cotinine as a therapeutic product. The verified literature contains no approved cotinine drug product and no registration trial. The neurological findings exist only in animal models (PMID 25100990, PMID 32300297).
3. Research-use-only materials. Cotinine reference standards and analytical materials are supplied for laboratory research and quantification work of the kind described in LC-MS/MS studies (PMID 31756277). Research-use-only material is not an approved medicine and carries no clinical labelling.
4. Compounding. Pharmacy compounding frameworks generally attach to substances with an approved product, an applicable monograph or listing on a regulator's permitted bulk-substance list. No verified study in this set documents cotinine as a compounded medicine.

This section describes regulatory categories in general terms and is not legal advice; rules differ by country and by state, and current agency listings are the authoritative source.

Limits of the evidence in Module 6: regulatory classification changes over time and is jurisdiction-specific, and none of the verified papers is a regulatory document. The absence of an approval in this literature set says nothing about pending or future filings.

What the Studies Did Not Test

Reading this body of work as a whole, the gaps are as important as the findings:

• No human efficacy trial. Fear extinction and Alzheimer-like pathology outcomes were observed in animal models (PMID 32300297, PMID 25100990); no verified study tested cognition, mood or anxiety endpoints in people given cotinine.
• No human dose-ranging. The verified papers do not establish a dose-response relationship for cotinine in humans, and the rodent pharmacokinetic work used smoke exposure (PMID 31756277).
• No reproductive safety data in humans. The oocyte deterioration signal is from mice (PMID 35191979), and the canine semen work was analytical detection (PMID 39728938).
• No separation of cotinine from smoking. Human studies measured cotinine as an exposure index alongside inflammatory and oxidative markers (PMID 36147199), so the metabolite's independent contribution was not isolated.
• No long-term follow-up. Cessation outcomes were reported in a perioperative context (PMID 30579712), and population concentration trends were descriptive (PMID 24291557); neither followed cotinine administration over years.

The literature therefore supports two well-evidenced statements — cotinine is a reliable biomarker of tobacco and nicotine exposure, and cotinine is pharmacologically active in experimental systems — while leaving its clinical effects in humans untested. This page is educational only and is not medical advice.

References

• First Evidence of Cotinine in Canine Semen Reveals Tobacco Smoke Exposure (Veterinary Sciences, 2024)
• Melatonin prevents oocyte deterioration due to cotinine exposure in mice (Biology of Reproduction, 2022)
• Cotinine Enhances Fear Extinction and Astrocyte Survival by Mechanisms Involving the Nicotinic Acetylcholine Receptors Signaling (Frontiers in Pharmacology, 2020)
• Estimation and comparison of serum cotinine level among individuals with smoking and tobacco chewing habit (Indian Journal of Dental Research, 2020)
• In vivo quantification and pharmacokinetic studies of cotinine in mice after smoke exposure by LC-MS/MS (Biomedical Chromatography, 2020)
• Revised and extended serum cotinine cut-offs to classify smokers and non-smokers (Biomarkers, 2018)
• Cotinine Testing Improves Smoking Cessation Before Total Joint Arthroplasty (The Journal of Arthroplasty, 2019)
• Detection of Vascular Inflammation and Oxidative Stress by Cotinine in Smokers: Measured Through Interleukin-6 and Superoxide Dismutase (International Journal of General Medicine, 2022)
• Urinary Cotinine Level in Indonesian Children Exposed to Domestic Cigarette Smoke (Journal of Natural Science, Biology, and Medicine, 2018)
• Nicotine and its metabolite cotinine target MD2 and inhibit TLR4 signaling (Innovation, 2021)
• Trends in serum cotinine concentrations among daily cigarette smokers: data from NHANES 1999-2010 (Science of the Total Environment, 2014)
• Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice (Frontiers in Aging Neuroscience, 2014)